Perioperative use of prothrombin complex concentrates

Minerva Anestesiologica

Volumn 78, Issue 3, 2012, Pages 358-368

  Colomina, M J ^a   Diez Lobo A ^b   Garutti, I ^c   Gomez Luque A ^d   Llau, J V ^e   Pita, E ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL GENERAL DE SEGOVIA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f UNIVERSITY OF A CORUÑA   (Spain)

Author keywords

Algorithms; Blood coagulation factors; Hemorrhage; Prothrombin complex concentrates

Indexed keywords

ACENOCOUMAROL; ACTIVATED PROTHROMBIN COMPLEX; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 9 CONCENTRATE; DABIGATRAN; FRESH FROZEN PLASMA; HEPARIN; PROTHROMBIN COMPLEX; PROTHROMPLEX NF; RIVAROXABAN; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DETERMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; EMERGENCY SURGERY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERVOLEMIA; INTERNATIONAL NORMALIZED RATIO; LIVER FAILURE; LOW DRUG DOSE; NONHUMAN; OPTIMAL DRUG DOSE; PATIENT SAFETY; PERIOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; STROKE; VENOUS THROMBOEMBOLISM;

ALGORITHMS; ANTICOAGULANTS; ANTIDOTES; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BLOOD LOSS, SURGICAL; DISSEMINATED INTRAVASCULAR COAGULATION; DRUG MONITORING; EMERGENCIES; EVIDENCE-BASED MEDICINE; HEMORRHAGE; HEMOSTATICS; HUMANS; LIVER FAILURE; PERIOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOEMBOLISM; VITAMIN K;

EID: 84857597001     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Samama CM. Prothrombin complex concentrates: a brief review. Eur J Anesthesiol 2008;25:784-789.
2. Liumbruno G, Bernnardello F, Lattanzio A, Piccoli P, Rossetti G and Italian Society of Transfusion Medicine and Immunohemathology (SIMTI) Working Party. Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates. Blood Transfus 2009;7:325-334.
3. Yasaka M, Sakata T, Naritomi H, Minematsu K. Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005;115:455-459.
4. Sociedad Española de Cardiología (Spanish Society of Cardiology) [Internet]. Available from www.secardiologia.es/secciones/electrofisiologia-y-arritmias [cited 2011, Sep 2].
5. Vigué B. Bench-to-bedside review: Optimising emergency reversal of vitamin K antagonists in severe hemorrhage - from theory to practice. Critical Care 2009;13:209.
6. Makris M, van Veen JJ, Maclean R. Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. J Thromb Thrombolysis 2010;29:171-181.
7. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996;348:423-428.
8. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685-2692.
9. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Hemost 2009;101:367-372.
10. Ost D, Tepper J, Mihara H et al. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA 2005;294:706-715.
11. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al. GRADE: an emerging consensus on rating quality of evidence and strenght of recommendations. Br Med J 2008;336:924-926.
12. Taberner DA, Thomson JM, Poller L. Comparison of prothrombin complex concentrate and vitamin K1 in oral anticoagulant reversal. Br Med J 1976;2:83-5.
13. Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract 2008;82:1614-1622.
14. Hoffman M, Monroe DM. Rethinking the coagulation cascade. Curr Hematol Rep 2005;4:391-396.
15. Páramo JA, Panizo E, Pegenaute C, Lecumberri R. Coagulación 2009: una visión moderna de la hemostasia. Rev Med Univ Navarra 2009;53:19-23.
16. Scott LJ. Prothrombin Complex Concentrate (Beriplex ® P/N). Drugs 2009;69:1977-1984.
17. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin complex concentrate (Beriplex ® P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Hemost 2008;6:622-631.
18. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg 2009;108:1433-1446.
19. Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management - fresh frozen plasma. Best Practice & Research Clinical Anesthesiology 2010;24:51-64.
20. Holland LL, Foster TM, Marlar RA, Brooks JP. Fresh frozen plasma is ineffective for correcting minimally elevated international normalized ratios. Transfusion 2005;45:1234-1235.
21. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Hemost 1997;77:477-480.
22. Moog R, Reichenberg S, Hoburg A, Müller N. Quality of methylene-blue-treated fresh-frozen stored up to 27 months. Transfusion 2010;50:516-518.
23. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 2000;14:458-4561.
24. Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. Anesthesiology 2008;109:918-26.
25. Grobler C, Callum JC, McCluskey SA. Reversal of vitamin K antagonists prior to urgent surgery. Can J Anesth 2010;57:458-467.
26. Spahn DR, Cerny V, Coats TJ, Duranteau J, Fernández- Mondéjar E, Gordini G et al. Management of bleeding following major trauma: a European guideline. Critical Care 2007,11:R17.
27. Pernod G, Godier A, Gozalo C, Tremey B, Sié P. French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 2010;126:167-174.
28. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol 2008;83:137-143.
29. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999;45:1113-1118.
30. Griffee MJ, DeLoughery TG, Thorborg PA. Coagulation management in massive bleeding. Curr Opin Anesthesiol 2010;23:263-268.
31. Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol 2007;73:401-415.
32. Bruce D, Nokes TJC. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care 2008;12:R105.
33. Rossaint R, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E et al. Management of bleeding following major trauma: an updated European guideline. Critical Care 2010;14:R52.
34. Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G et al. Goal directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen. Critical Care 2010;14:R55.
35. Cushing M, Shaz BH. Blood transfusion in trauma patients: unresolved questions. Minerva Anestesiol 2011;77:349-359.
36. Elg M, Carlsson S and Gustafsson D. Effect of Activated Prothrombin Complex concentrate or Recombinant Factor VIIa on the Bleeding Time and Thrombus Formation During Anticoagulation with a Direct Thrombin Inhibitor. Thromb Res 2001;101:145-157.
37. van Ryn J, Stangier J, Hertter S, Haertter S, Liesenfeld KH, Wienen W, Feuring M et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor:interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Hemost 2010;103:1116-1127.
38. Heindl B, Spannagl M. New oral anticoagulants. Consecuences for perioperative coagulaction diagnostics and therapy]. Anesthesist 2009;58:1252-1255.
39. Levy JH, Azran M. Anesthetic concerns for patients with coagulopathy. Curr Opin Anesthesiol 2010;23:400-405.
40. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Hemost 2010;103:572-585.
41. Sorensen S, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates - evaluation of safety and thrombogenicity. Critical Care 2011;15:201-209.
42. Gatt A, Riddell A, van Veen JJ, Kitchen S, Tuddenham EG, Makris M. Optimizing warfarin reversal: an ex-vivo study. J Thromb Hemostas 2009;7:1123-1127.
43. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res 2007;121:9-16.
44. van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 2006;118:313-320.
45. Schulman S. Clinical practice: Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003;349: 675-683.
46. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists. Chest 2008;133:160S-98S.